PRAVASTATIN SODIUM

First approved in 1991

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H35O7.Na
Molecular Weight	446.5096
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@@H]12

InChI

InChIKey=VWBQYTRBTXKKOG-IYNICTALSA-M

InChI=1S/C23H36O7.Na/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28;/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28);/q;+1/p-1/t13-,14-,16+,17+,18+,19-,20-,22-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C23H35O7
Molecular Weight	423.5198
Charge	-1
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	8 / 8
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019898s066lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.drugs.com/pravastatin.html | https://www.ncbi.nlm.nih.gov/pubmed/16960448 | http://reference.medscape.com/drug/pravachol-pravastatin-342460 | https://www.drugbank.ca/drugs/DB00175

Pravastatin (marketed as Pravachol or Selektine) is a member of the drug class of statins, used in combination with diet, exercise, and weight loss for lowering cholesterol and preventing cardiovascular disease. Pravastatin acts as a lipoprotein-lowering drug through two pathways. In the major pathway, pravastatin inhibits the function of hydroxymethylglutaryl-CoA (HMG-CoA) reductase. As a reversible competitive inhibitor, pravastatin sterically hinders the action of HMG-CoA reductase by occupying the active site of the enzyme. Taking place primarily in the liver, this enzyme is responsible for the conversion of HMG-CoA to mevalonate in the rate-limiting step of the biosynthetic pathway for cholesterol. Pravastatin also inhibits the synthesis of very-low-density lipoproteins, which are the precursor to low-density lipoproteins (LDL). These reductions increase the number of cellular LDL receptors, thus LDL uptake increases, removing it from the bloodstream. Pravastatin is primarily used for the treatment of dyslipidemia and the prevention of cardiovascular disease. It is recommended to be used only after other measures, such as diet, exercise, and weight reduction, have not improved cholesterol levels. The evidence for the use of pravastatin is generally weaker than for other statins. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT), failed to demonstrate a difference in all-cause mortality or nonfatal myocardial infarction/fatal coronary heart disease rates between patients receiving pravastatin 40 mg daily (a common starting dose) and those receiving usual care. Pravastatin is generally well tolerated; adverse reactions have usually been mild and transient. In 4-month-long placebo-controlled trials, 1.7% of Pravastatin-treated patients and 1.2% of placebo-treated patients were discontinued from treatment because of adverse experiences attributed to study drug therapy; this difference was not statistically significant.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
HMG-CoA reductase 49 Target ID: CHEMBL402 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11392538	Inhibitor 8504		1370.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Coronary heart disease 43 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019898s066lbl.pdf	Primary	Approved 8583	PRAVACHOL Approved Use Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Pravastatin sodium tablet, USP is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. ( 1.1) Reduce the risk of total mortality by reducing coronary death, MI, revascularization, stroke/TIA, and the progression of coronary atherosclerosis in patients with clinically evident CHD. ( 1.1) Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. ( 1.2) Reduce elevated serum TG levels in patients with hypertriglyceridemia. ( 1.2) Treat patients with primary dysbetalipoproteinemia who are not responding to diet. ( 1.2) Treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2) Limitations of use: Pravastatin sodium tablets, USP have not been studied in Fredrickson Types I and V dyslipidemias. ( 1.3) 1.1 Prevention of Cardiovascular Disease In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), pravastatin sodium tablets, USP are indicated to: reduce the risk of myocardial infarction (MI). reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. In patients with clinically evident CHD, pravastatin sodium tablet is indicated to: reduce the risk of total mortality by reducing coronary death. reduce the risk of MI. reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of stroke and stroke/transient ischemic attack (TIA). slow the progression of coronary atherosclerosis. 1.2 Hyperlipidemia Pravastatin sodium tablet is indicated: as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglyceride (TG) levels and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia ( Fredrickson Types IIa and IIb). 1 as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV). for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet. as an adjunct to diet and lifestyle modification for treatment of heterozygous familial hypercholesterolemia (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors are present in the patient. 1.3 Limitations of Use Pravastatin sodium has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). Launch Date 1991
Hypercholesterolemia 51 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019898s066lbl.pdf	Primary	Approved 8583	PRAVACHOL Approved Use Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Pravastatin sodium tablet, USP is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. ( 1.1) Reduce the risk of total mortality by reducing coronary death, MI, revascularization, stroke/TIA, and the progression of coronary atherosclerosis in patients with clinically evident CHD. ( 1.1) Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. ( 1.2) Reduce elevated serum TG levels in patients with hypertriglyceridemia. ( 1.2) Treat patients with primary dysbetalipoproteinemia who are not responding to diet. ( 1.2) Treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2) Limitations of use: Pravastatin sodium tablets, USP have not been studied in Fredrickson Types I and V dyslipidemias. ( 1.3) 1.1 Prevention of Cardiovascular Disease In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), pravastatin sodium tablets, USP are indicated to: reduce the risk of myocardial infarction (MI). reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. In patients with clinically evident CHD, pravastatin sodium tablet is indicated to: reduce the risk of total mortality by reducing coronary death. reduce the risk of MI. reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of stroke and stroke/transient ischemic attack (TIA). slow the progression of coronary atherosclerosis. 1.2 Hyperlipidemia Pravastatin sodium tablet is indicated: as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglyceride (TG) levels and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia ( Fredrickson Types IIa and IIb). 1 as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV). for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet. as an adjunct to diet and lifestyle modification for treatment of heterozygous familial hypercholesterolemia (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors are present in the patient. 1.3 Limitations of Use Pravastatin sodium has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). Launch Date 1991
Mixed dyslipidemia 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019898s066lbl.pdf	Primary	Approved 8583	PRAVACHOL Approved Use Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Pravastatin sodium tablet, USP is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. ( 1.1) Reduce the risk of total mortality by reducing coronary death, MI, revascularization, stroke/TIA, and the progression of coronary atherosclerosis in patients with clinically evident CHD. ( 1.1) Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. ( 1.2) Reduce elevated serum TG levels in patients with hypertriglyceridemia. ( 1.2) Treat patients with primary dysbetalipoproteinemia who are not responding to diet. ( 1.2) Treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2) Limitations of use: Pravastatin sodium tablets, USP have not been studied in Fredrickson Types I and V dyslipidemias. ( 1.3) 1.1 Prevention of Cardiovascular Disease In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), pravastatin sodium tablets, USP are indicated to: reduce the risk of myocardial infarction (MI). reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. In patients with clinically evident CHD, pravastatin sodium tablet is indicated to: reduce the risk of total mortality by reducing coronary death. reduce the risk of MI. reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of stroke and stroke/transient ischemic attack (TIA). slow the progression of coronary atherosclerosis. 1.2 Hyperlipidemia Pravastatin sodium tablet is indicated: as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglyceride (TG) levels and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia ( Fredrickson Types IIa and IIb). 1 as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV). for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet. as an adjunct to diet and lifestyle modification for treatment of heterozygous familial hypercholesterolemia (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors are present in the patient. 1.3 Limitations of Use Pravastatin sodium has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). Launch Date 1991
Dysbetalipoproteinemia 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019898s066lbl.pdf	Primary	Approved 8583	PRAVACHOL Approved Use Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Pravastatin sodium tablet, USP is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. ( 1.1) Reduce the risk of total mortality by reducing coronary death, MI, revascularization, stroke/TIA, and the progression of coronary atherosclerosis in patients with clinically evident CHD. ( 1.1) Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. ( 1.2) Reduce elevated serum TG levels in patients with hypertriglyceridemia. ( 1.2) Treat patients with primary dysbetalipoproteinemia who are not responding to diet. ( 1.2) Treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2) Limitations of use: Pravastatin sodium tablets, USP have not been studied in Fredrickson Types I and V dyslipidemias. ( 1.3) 1.1 Prevention of Cardiovascular Disease In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), pravastatin sodium tablets, USP are indicated to: reduce the risk of myocardial infarction (MI). reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. In patients with clinically evident CHD, pravastatin sodium tablet is indicated to: reduce the risk of total mortality by reducing coronary death. reduce the risk of MI. reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of stroke and stroke/transient ischemic attack (TIA). slow the progression of coronary atherosclerosis. 1.2 Hyperlipidemia Pravastatin sodium tablet is indicated: as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglyceride (TG) levels and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia ( Fredrickson Types IIa and IIb). 1 as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV). for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet. as an adjunct to diet and lifestyle modification for treatment of heterozygous familial hypercholesterolemia (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors are present in the patient. 1.3 Limitations of Use Pravastatin sodium has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). Launch Date 1991

C_max

Value	Dose	Co-administered	Analyte	Population
27.4 μg/L EXPERIMENT https://link.springer.com/article/10.2165/00003088-200039060-00002	19.2 mg single, oral dose: 19.2 mg route of administration: Oral experiment type: SINGLE co-administered:		PRAVASTATIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
299.56 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00829309	80 mg single, oral dose: 80 mg route of administration: oral experiment type: single co-administered:	PRAVASTATIN plasma	Homo sapiens population: healthy age: sex: food status: Fed
251.86 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00829309	80 mg single, oral dose: 80 mg route of administration: oral experiment type: single co-administered:	PRAVASTATIN plasma	Homo sapiens population: healthy age: sex: food status: Fed
273.32 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00829309	80 mg single, oral dose: 80 mg route of administration: oral experiment type: single co-administered:	PRAVASTATIN plasma	Homo sapiens population: healthy age: sex: food status: Fed
241.29 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00829309	80 mg single, oral dose: 80 mg route of administration: oral experiment type: single co-administered:	PRAVASTATIN plasma	Homo sapiens population: healthy age: sex: food status: Fed
66.2 μg × h/mL EXPERIMENT https://link.springer.com/article/10.2165/00003088-200039060-00002	19.2 mg single, oral dose: 19.2 mg route of administration: Oral experiment type: SINGLE co-administered:	PRAVASTATIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.77 h EXPERIMENT https://link.springer.com/article/10.2165/00003088-200039060-00002	19.2 mg single, oral dose: 19.2 mg route of administration: Oral experiment type: SINGLE co-administered:		PRAVASTATIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
Kv1.3 15 OAT1 725 OAT2 153 OAT3 747 OAT4 150 P-gp 1741	OATP1B1 503 OATP1B3 435 OATP2B1 122 BCRP 697 MRP1 113 MRP5 41 MRP2 252 P-gp 2052 MRP4 91 MRP3 58 OATP2 11

Drug as perpetrator

Target	Modality	Activity
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11250868/ \| https://pubmed.ncbi.nlm.nih.gov/17064205/	no
OAT2 155	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/14978359/	weak [IC50 352 uM]
OAT1 730	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/14978359/	weak [IC50 408 uM]
OAT4 150	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/14978359/	weak [IC50 591 uM]
OAT3 749	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/14978359/	yes [IC50 13.7 uM]
Kv1.3 30	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/33437096/	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019898s060lbl.pdf	no	no (co-administration study) Comment: see https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019898s060lbl.pdf#page=19 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019898s060lbl.pdf
BCRP 697	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30217571/ \| https://pubmed.ncbi.nlm.nih.gov/15901800/	yes
MRP1 113	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30217571/	yes
MRP2 252	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30217571/ \| https://pubmed.ncbi.nlm.nih.gov/15901800/	yes
MRP3 58	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30217571/	yes
MRP4 91	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30217571/	yes
MRP5 41	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30217571/	yes
OATP1B3 435	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/19785645/	yes
OATP2 11	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/11356905/ \| https://pubmed.ncbi.nlm.nih.gov/10601278/	yes
OATP2B1 122	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/19785645/	yes
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30217571/ \| https://pubmed.ncbi.nlm.nih.gov/15901800/	yes
OATP1B1 503	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/19785645/ \| https://pubmed.ncbi.nlm.nih.gov/15901800/	yes	yes (co-administration study) Comment: Coadministration with cyclosporine (inhibitor): AUC increased 5-10 fold Sources: https://pubmed.ncbi.nlm.nih.gov/19785645/ \| https://pubmed.ncbi.nlm.nih.gov/15901800/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:63618	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63618
ChemicalBook	CB92544321	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB92544321
eMolecules	3716196	https://www.emolecules.com/cgi-bin/more?vid=3716196
MolPort	MolPort-006-167-482	https://www.molport.com/shop/molecule-link/MolPort-006-167-482
ZINC	ZINC000003798763	http://zinc15.docking.org/substances/ZINC000003798763

PubMed

Title	Date	PubMed
Compactin enhances osteogenesis in murine embryonic stem cells.	2001-06-08	11394905
Statin therapy and the prevention of dementia.	2001-06	11405825
Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients.	2001-06	11404165
Simvastatin-associated memory loss.	2001-06	11401190
HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress.	2001-06	11397700
Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection.	2001-06	11389707
Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site.	2001-06	11385505
Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction.	2001-06	11380811
Randomized clinical trials and recent patterns in the use of statins.	2001-06	11376310
The pravastatin inflammation CRP evaluation (PRINCE): rationale and design.	2001-06	11376301
PRINCE's prospects: statins, inflammation, and coronary risk.	2001-06	11376298
Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes.	2001-06	11356905
Limitation of heart growth in neonatal piglets by simvastatin and atorvastatin: comparison with pravastatin.	2001-06	11356632
Synthesis and biological evaluations of condensed pyridine and condensed pyrimidine-based HMG-CoA reductase inhibitors.	2001-05-21	11392538
Summaries for patients. Benefits of lowering cholesterol levels in older patients.	2001-05-15	11357858
Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.	2001-05-15	11352694
[Statins as new therapeutic possibility in osteoporosis?].	2001-05-11	11402915
Protective effects of Saiko-ka-ryukotsu-borei-to (Chai-Hu-Jia-Long-Gu-Mu-Li-Tang) against atherosclerosis in Kurosawa and Kusanagi-hypercholesterolemic (KHC) rabbits.	2001-05	11394941
Statin induced myopathy does not show up in MIBI scintigraphy.	2001-05	11388581
[Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study].	2001-05	11388336
What do the statin trials tell us?	2001-05	11383375
The in vitro inhibitory effect of tannin derivatives on 3-hydroxy-3-methylglutaryl-coenzyme a reductase on vero cells.	2001-05	11359999
Interactions of leptin and thyrotropin 24-hour secretory profiles in short normal children.	2001-05	11344208
Effects of 1-year treatment with fluvastatin or pravastatin on bone.	2001-05	11343673
Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels.	2001-05	11320359
Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial.	2001-05	11320358
Cholesterol ester accumulation: an immediate consequence of acute in vivo ischemic renal injury.	2001-05	11318945
Reassuring effect of pravastatin on natural killer cell activity in stable renal transplant patients.	2001-04-27	11374422
[Acute coronary syndrome. Early lipid reduction decreases risk of recurrence].	2001-04-19	11368001
New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist.	2001-04-19	11334766
Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.	2001-04-17	11306519
Assessing the results: phase 1 hyperlipidemia outcomes in 27 health plans.	2001-04-16	11311193
[Effect on plasma fibrinogen of hypercholesterolaemia treatment with pravastatin].	2001-04-15	11334580
New OTC drugs and devices 2000: a selective review.	2001-04-12	11297337
Safety of statins (hydroxymethyl glutaryl coenzyme a reductase inhibitors): different mechanisms of metabolism and drug transport may have clinical relevance.	2001-04-09	11295969
Pravastatin attenuates lower torso ischaemia-reperfusion-induced lung injury by upregulating constitutive endothelial nitric oxide synthase.	2001-04	11359328
Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).	2001-04	11315826
Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.	2001-04	11310513
Pravastatin and coronary heart disease.	2001-03-31	11293615
[PATE Study [Pravastatin anti-Atherosclerosis Trial in the Elderly Study]].	2001-03	11347113
[CARE[ Cholesterol and Recurrent Events Trial]].	2001-03	11347108
[REGRESS [The Regression Growth Evaluation Statin Study]].	2001-03	11347107
[LIPID study [Long-term Intervention with Pravastatin in Ischaemic Disease study]].	2001-03	11347106
[WOSCOPS [West of Scotland Coronary Prevention Study]].	2001-03	11347100
Is a statin a statin?	2001-03	11321864
Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population.	2001-03	11318529
[Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study].	2001-03	11307791
[Treatment with statins for the reduction of cardiovascular risk].	2001-03	11307779
Medical-economical aspects of high sensitivity C-reactive protein assay for the prediction of coronary heart disease. An analysis in Germany and Italy.	2001-03	11305529
Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors.	2001-01	11367508

Patents

Sample Use Guides

In Vivo Use Guide

May be beneficial for prophylaxis of cardiovascular events in at-risk patients, even if patients have normal levels of cholesterol. 10-40 mg PO qDay; not to exceed 80 mg/day Initiate with 10 mg qHS if taking immunosuppressants like cyclosporine concurrently; not to exceed 20 mg/day Limit maximum to 40 mg/day if taking concurrently with clarithromycin Dose adjustments should be made at intervals of 4 weeks or more; individualize dosing according to baseline LDL cholesterol levels

Route of Administration: Oral

In Vitro Use Guide

Pravastatin activity was evaluated using cellular steroidgenesis assay in Hep G2cells (human hepatoma cell line) cultured with 5% lipoprotein deficient serum containing medium for 48 h. The activities were determined by decreased incorporation of sodium [2-14C] acetate into non-saponifiable lipids.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:12:40 GMT 2025` Edited by `admin` on `Mon Mar 31 18:12:40 GMT 2025`
Record UNII	3M8608UQ61
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PRAVIGARD PAC COMPONENT PRAVASTATIN SODIUM

Preferred Name

English

PRAVASTATIN SODIUM

Official Name

English

1-NAPHTHALENEHEPTANOIC ACID, 1,2,6,7,8,8A-HEXAHYDRO-.BETA.,D,6-TRIHYDROXY-2-METHYL-8-(2-METHYL-1-OXOBUTOXY)-, MONOSODIUM SALT, (1S-(1.ALPHA.(.BETA.S*,DS*),2.ALPHA.,6.ALPHA.,8.BETA.(R*),8A.ALPHA.))-

Common Name

English

Pravastatin sodium [WHO-DD]

Common Name

English

PRAVASTATIN SODIUM [VANDF]

Common Name

English

PRAVACHOL

Brand Name

English

SQ-31000

Code

English

PRAVASTATIN SODIUM [EP MONOGRAPH]

Common Name

English

PRAVASTATIN SODIUM [JAN]

Common Name

English

SODIUM (+)-(.BETA.R,DR,1S,2S,6S,8S,8AR)-1,2,6,7,8,8A-HEXAHYDRO-.BETA.,D,6,8-TETRAHYDROXY-2-METHYL-1-NAPHTHALENEHEPTANOATE, 8-((2S)-2-METHYLBUTYRATE)

Common Name

English

CS-514

Code

English

PRAVASTATIN SODIUM [ORANGE BOOK]

Common Name

English

SQ-31,000

Code

English

NSC-759253

Code

English

PRAVASTATIN SODIUM [USP-RS]

Common Name

English

PRAVASTATIN SODIUM [USAN]

Common Name

English

PRAVASTATIN SODIUM [USP MONOGRAPH]

Common Name

English

DEHYPOTIN PROTECT

Brand Name

English

PRAVASTATIN SODIUM [MART.]

Common Name

English

PRAVASTATIN SODIUM [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1655